Silence Therapeutics plc (SLNCF)
OTCMKTS
· Delayed Price · Currency is USD
1.470
+1.470 (0.00%)
Feb 28, 2025, 3:00 PM EST
Silence Therapeutics Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Revenue | 43.26 | 31.64 | 21.66 | 12.42 | 5.48 | Upgrade
|
Revenue Growth (YoY) | 36.71% | 46.12% | 74.43% | 126.59% | 2145.49% | Upgrade
|
Cost of Revenue | 11.81 | 12.87 | 13.46 | 7.46 | 3.76 | Upgrade
|
Gross Profit | 31.45 | 18.78 | 8.19 | 4.96 | 1.72 | Upgrade
|
Selling, General & Admin | 26.88 | 26.22 | 25.68 | 20.01 | 13.98 | Upgrade
|
Research & Development | 54.15 | 44.99 | 33.73 | 30.77 | 20.21 | Upgrade
|
Other Operating Expenses | - | - | - | - | -1.49 | Upgrade
|
Operating Expenses | 81.03 | 71.21 | 59.41 | 50.77 | 32.7 | Upgrade
|
Operating Income | -49.58 | -52.43 | -51.22 | -45.81 | -30.98 | Upgrade
|
Interest Expense | - | - | - | -0.01 | -0.02 | Upgrade
|
Interest & Investment Income | - | - | - | 0.01 | 0.13 | Upgrade
|
Currency Exchange Gain (Loss) | 0.65 | -2.64 | 1.29 | -0.04 | -5.17 | Upgrade
|
Other Non Operating Income (Expenses) | 4.47 | 1.8 | 0.28 | - | - | Upgrade
|
EBT Excluding Unusual Items | -44.46 | -53.27 | -49.65 | -45.86 | -36.04 | Upgrade
|
Pretax Income | -44.46 | -53.27 | -49.65 | -45.86 | -36.04 | Upgrade
|
Income Tax Expense | 0.85 | 0.96 | 0.69 | -6.45 | -3.49 | Upgrade
|
Net Income | -45.31 | -54.23 | -50.33 | -39.41 | -32.55 | Upgrade
|
Net Income to Common | -45.31 | -54.23 | -50.33 | -39.41 | -32.55 | Upgrade
|
Shares Outstanding (Basic) | 46 | 37 | 32 | 30 | 27 | Upgrade
|
Shares Outstanding (Diluted) | 46 | 37 | 32 | 30 | 27 | Upgrade
|
Shares Change (YoY) | 24.69% | 15.21% | 8.58% | 8.78% | 8.85% | Upgrade
|
EPS (Basic) | -0.98 | -1.46 | -1.56 | -1.33 | -1.19 | Upgrade
|
EPS (Diluted) | -0.98 | -1.46 | -1.56 | -1.33 | -1.19 | Upgrade
|
Free Cash Flow | -67.85 | -49.52 | -57.22 | 5.5 | -11.29 | Upgrade
|
Free Cash Flow Per Share | -1.47 | -1.33 | -1.78 | 0.19 | -0.41 | Upgrade
|
Gross Margin | 72.70% | 59.34% | 37.83% | 39.94% | 31.34% | Upgrade
|
Operating Margin | -114.62% | -165.70% | -236.53% | -369.02% | -565.49% | Upgrade
|
Profit Margin | -104.74% | -171.37% | -232.44% | -317.44% | -594.03% | Upgrade
|
Free Cash Flow Margin | -156.85% | -156.49% | -264.22% | 44.26% | -206.00% | Upgrade
|
EBITDA | -48.99 | -51.81 | -50.62 | -45.56 | -30.49 | Upgrade
|
EBITDA Margin | -113.25% | -163.74% | -233.78% | - | - | Upgrade
|
D&A For EBITDA | 0.59 | 0.62 | 0.6 | 0.25 | 0.5 | Upgrade
|
EBIT | -49.58 | -52.43 | -51.22 | -45.81 | -30.98 | Upgrade
|
EBIT Margin | -114.62% | -165.70% | -236.53% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.